Cargando…
Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study
BACKGROUND: Apatinib, a vascular endothelial growth factor receptor (VEGFR) blocker, has demonstrated encouraging antitumor activities and tolerable toxicities in various cancer types. Recurrent or metastatic adenoid cystic carcinoma of the head and neck (R/MACCHN) carries a poor prognosis, and trea...
Autores principales: | Zhu, Guopei, Zhang, Lin, Dou, Shengjin, Li, Rongrong, Li, Jiang, Ye, Lulu, Jiang, Wen, Dong, Minjun, Ruan, Min, Yang, Wenjun, Zhang, Chenping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111556/ https://www.ncbi.nlm.nih.gov/pubmed/33995600 http://dx.doi.org/10.1177/17588359211013626 |
Ejemplares similares
-
Combined all‐trans retinoic acid with low‐dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single‐center, secondary analysis of a phase II study
por: Ye, Lulu, et al.
Publicado: (2023) -
The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication
por: Dou, Shengjin, et al.
Publicado: (2021) -
Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial
por: Jiang, Wen, et al.
Publicado: (2023) -
Long‐term results of elective mucosal irradiation for head and neck cancer of unknown primary in Chinese population: The EMICUP study
por: Dou, Shengjin, et al.
Publicado: (2020) -
A feasibility and safety study of concurrent chemotherapy based on genetic testing in patients with high-risk salivary gland tumors: Preliminary results
por: Li, Rongrong, et al.
Publicado: (2018)